INTS Stock Risk & Deep Value Analysis
Intensity Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About INTS Stock
We analyzed Intensity Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INTS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
INTS Risk Analysis & Red Flags
What Could Go Wrong
The company's clinical trials could fail to meet primary endpoints or demonstrate sufficient efficacy/safety compared to existing treatments. This would render its core asset, INT230-6, unviable, leading to a substantial loss of investment as the company burns its remaining cash without a viable product.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
No revenue and persistent significant net losses ($11.6M FY25 loss).
- ⚠
Heavy reliance on dilutive capital raises (expanded $60M ATM program, recent 1-for-25 reverse split).
- ⚠
Market capitalization ($0.01B) is currently below its cash balance ($11.9M), indicating extreme investor skepticism about future value creation.
- ⚠
Analyst median price target ($4.50) is below the current stock price ($5.70), despite a 'Moderate Buy' consensus.
Upcoming Risk Events
- 📅
Negative or inconclusive results from ongoing clinical trials
- 📅
Slower-than-expected patient enrollment for INVINCIBLE-4
- 📅
Failure to secure additional financing leading to cash crunch
When to Reconsider
- 🚪
Failure of INT230-6 to meet primary endpoints in any ongoing Phase 2 trials.
- 🚪
Inability to extend cash runway beyond Q2 2027 without significant dilution (>50% share increase).
- 🚪
Major competitor launches a highly effective, directly competing therapy for targeted solid tumors.
Unlock INTS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Intensity Therapeutics Inc (INTS) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
5
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Visit Intensity Therapeutics Inc WebsiteInvestment Thesis
Intensity Therapeutics offers a highly speculative, high-reward investment opportunity based on the potential of its lead candidate, INT230-6, to become a significant treatment for difficult-to-treat solid tumors. While currently unprofitable and requiring substantial future financing, positive early Phase 2 data, an extended cash runway, and a unique mechanism of action provide a slim but compelling pathway for a potential 10x return if clinical breakthroughs occur, leading to a major strategic partnership or acquisition.
Is INTS Stock Undervalued?
Unlock the full AI analysis for INTS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
INTS Price Targets & Strategy
12-Month Target
$6.50
Bull Case
$75.00
Bear Case
$1.00
Valuation Basis
Based on a modest 15% increase in implied pipeline value due to continued positive clinical data and extended cash runway, tempered by ongoing dilution risk and market cap currently below cash.
Entry Strategy
Given high volatility and speculative nature, consider dollar-cost averaging on dips towards the 52-week low or significant support levels, allocating only a very small, speculative portion of the portfolio.
Exit Strategy
Take 25-50% profit upon announcement of a major clinical milestone (e.g., successful Phase 2 completion, initiation of Phase 3, or significant partnership). Implement a strict stop-loss if clinical trial results are negative or cash runway diminishes without new funding.
Portfolio Allocation
0.5-1% for aggressive risk tolerance; not suitable for conservative or moderate portfolios.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is INTS Financially Healthy?
Valuation
P/E Ratio
-1.90
PEG Ratio
-0.12
Price/Book
10.70
Other
Beta (Volatility)
-0.41
Does INTS Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Potentially Expanding (If INT230-6 achieves significant clinical success and regulatory approval, its IP could form the basis of a future moat.)
Moat Sources
1 Identified
Currently very fragile. Durability is entirely dependent on proving superior efficacy/safety in large-scale clinical trials and obtaining regulatory approval, which is a long and uncertain path. Without this, the IP holds little value.
Moat Erosion Risks
- •Clinical trial failure or less-than-stellar results compared to existing or emerging therapies.
- •Competitive landscape evolving rapidly with potentially superior or more cost-effective treatments.
- •Challenges to the intellectual property by competitors.
INTS Competitive Moat Analysis
Sign up to see competitive advantages
INTS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (High volatility and speculative nature suggest retail interest, but no specific positive or negative trends are available in the provided data.)
Institutional Sentiment
Neutral (Analyst consensus is 'Moderate Buy' from 6 analysts, but the median price target of $4.50 is below the current price of $5.70, suggesting caution or a disconnect. No specific upgrades/downgrades or institutional ownership percentages were detailed.)
Insider Activity (Form 4)
No specific Form 4 filings detailing CEO/CFO buys/sells in the last 90 days. Total institutional ownership % unavailable.
Options Flow
Normal options activity (No specific unusual options activity data was provided in the research.)
Earnings Intelligence
Next Earnings
2026-05-12 (Expected Q1 2026)
Surprise Probability
High
Historical Earnings Pattern
Likely high stock price volatility around earnings reports, driven by clinical trial updates and financing news, rather than traditional financial metrics due to lack of revenue.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (No specific direct clinical-stage competitor with a similar drug mechanism and indication focus was detailed in the research. The competitive landscape is broad, encompassing major oncology players like Merck or Bristol Myers Squibb if successful.)
Market Share Trend
Losing (Currently has zero market share in a highly competitive space with established players and many new therapies emerging.)
Valuation vs Peers
N/A (Traditional valuation metrics like P/E, P/S, EV/EBITDA are not applicable due to no revenue or profits. Comparing P/B of 1.25 to early-stage peers would require specific peer data which is not available.)
Competitive Advantages
- •Unique mechanism of action for INT230-6 (direct intratumoral injection of anti-cancer agents to overcome tumor microenvironment challenges).
- •Encouraging early Phase 2 clinical data showing promising disease control rates and survival in difficult-to-treat solid tumors.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive INTS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Expected May 12, 2026)
- •Further clinical updates from IT-01 and INVINCIBLE-4 trials
- •Progress on INVINCIBLE-4 enrollment and protocol amendment implementation
Medium-Term (6-18 months)
- •Announcement of Phase 2 trial completion for INT230-6
- •Initiation of Phase 3 clinical trials
- •Potential strategic partnership or licensing agreement discussions
Long-Term (18+ months)
- •Regulatory approval and commercialization of INT230-6
- •Expansion of INT230-6 into additional solid tumor indications
- •Acquisition by a larger pharmaceutical company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INTS?
- ✓
Consistent positive updates and progression in clinical trial results for INT230-6, particularly regarding overall survival and objective response rates.
- ✓
Announcement of a significant strategic partnership or non-dilutive financing deal that extends the cash runway well beyond Q2 2027 without substantial shareholder dilution.
Bull Case Analysis
See what could go right with Premium
Competing with INTS
See how Intensity Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Intensity Therapeutics Inc INTS | — | 3.5 | -1.9 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Intensity Therapeutics Inc (INTS)?
As of April 3, 2026, Intensity Therapeutics Inc has a DVR Score of 3.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Intensity Therapeutics Inc use?
INTS is the ticker symbol for Intensity Therapeutics Inc. The company trades on the NCM.
What is the risk level for INTS stock?
Our analysis rates Intensity Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of INTS?
Intensity Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -1.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Intensity Therapeutics Inc's revenue growing?
Intensity Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is INTS stock profitable?
Intensity Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the INTS DVR analysis updated?
Our AI-powered analysis of Intensity Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INTS (Intensity Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.